US FDA’s Familiar Drug Pricing To-Do List

 
• By Michael McCaughan
  
A provision in a Trump executive order on drug pricing looking to limit anti-competitive behavior seems largely benign. (Shutterstock)

More from Pricing Debate

More from Compliance